Acadia Pharmaceuticals (ACAD) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for Acadia Pharmaceuticals (ACAD) over the last 10 years, with Q3 2025 value amounting to $0.42.
- Acadia Pharmaceuticals' EPS (Weighted Average and Diluted) rose 11000.0% to $0.42 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.55, marking a year-over-year increase of 9871.79%. This contributed to the annual value of $1.36 for FY2024, which is 46385.06% up from last year.
- Per Acadia Pharmaceuticals' latest filing, its EPS (Weighted Average and Diluted) stood at $0.42 for Q3 2025, which was up 11000.0% from $0.16 recorded in Q2 2025.
- In the past 5 years, Acadia Pharmaceuticals' EPS (Weighted Average and Diluted) registered a high of $0.86 during Q4 2024, and its lowest value of -$268.51 during Q4 2021.
- Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.04 (2021), whereas its average is -$14.92.
- As far as peak fluctuations go, Acadia Pharmaceuticals' EPS (Weighted Average and Diluted) crashed by 13529.41% in 2023, and later surged by 190000.0% in 2024.
- Acadia Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarter) stood at -$268.51 in 2021, then skyrocketed by 99.9% to -$0.26 in 2022, then soared by 208.46% to $0.28 in 2023, then skyrocketed by 209.07% to $0.86 in 2024, then crashed by 51.39% to $0.42 in 2025.
- Its EPS (Weighted Average and Diluted) was $0.42 in Q3 2025, compared to $0.16 in Q2 2025 and $0.11 in Q1 2025.